Overview

Alpha Lipoic Acid in Ulcerative Colitis

Status:
Not yet recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
This study aims at evaluating the efficacy and safety of alpha-lipoic acid as adjuvant therapy to mesalamine in patients with mild to moderate ulcerative colitis due to its effect as anti-oxidant and anti-inflammatory drug which can help to improve disease.
Phase:
N/A
Details
Lead Sponsor:
Tanta University
Treatments:
Mesalamine
Thioctic Acid